Literature DB >> 17208578

Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.

Hideki Watanabe1, Yasuhiro Inoue, Keiichi Uchida, Yoshinaga Okugawa, Junichiro Hiro, Eiki Ojima, Minako Kobayashi, Chikao Miki, Masato Kusunoki.   

Abstract

This is a first pediatric case about the efficacy of octreotide for improving symptoms of malignant bowel obstruction. A 12-year-old boy was referred to our hospital for treatment of transverse colon cancer with peritoneal dissemination. A transverse colectomy was undertaken with postoperative adjuvant chemotherapy. Seven months later, severe abdominal symptoms occurred caused by incomplete bowel obstruction owing to tumor progression. The patient's quality of life decreased with a resultant disturbed mental condition. His parents sought to stop chemotherapy and for him to receive palliative care at home. We suggested nasogastric tube placement, but this was rejected. After obtaining informed consent, octreotide was administered intravenously. After 1 week, abdominal symptoms improved and the boy's complaints stopped. He had a good appetite and was able to eat small amounts of food. He was able to spend his final 2 months at home without nausea and in his family surroundings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17208578     DOI: 10.1016/j.jpedsurg.2006.09.025

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  2 in total

1.  Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction.

Authors:  Tsunehiro Takahashi; Yoshiro Saikawa; Takahiro Igarashi; Shinichi Tsuwano; Koshi Kumagai; Rieko Nakamura; Takashi Ooyama; Norihito Wada; Hiroya Takeuchi; Hiromasa Takaishi; Yuko Kitagawa
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

2.  Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy.

Authors:  Koshi Kumagai; Yoshiro Saikawa; Kazumasa Fukuda; Ryo Ito; Takahiro Igarashi; Shinichi Tsuwano; Rieko Nakamura; Tsunehiro Takahashi; Hiroya Takeuchi; Yuko Kitagawa
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.